Skip to main content

Advertisement

SpringerLink
Log in

Epidermal Growth Factor Receptor as a Therapeutic Target in Glioblastoma

  • Original Paper
  • Published:
NeuroMolecular Medicine Aims and scope Submit manuscript

Abstract

Glioblastoma represents one of the most challenging problems in neurooncology. Among key elements driving its behavior is the transmembrane epidermal growth factor receptor family, with the first member epidermal growth factor receptor (EGFR) centered in most studies. Engagement of the extracellular domain with a ligand activates the intracellular tyrosine kinase (TK) domain of EGFR, leading to autophosphorylation and signal transduction that controls proliferation, gene transcription, and apoptosis. Oncogenic missense mutations, deletions, and insertions in the EGFR gene are preferentially located in the extracellular domain in glioblastoma and cause constitutive activation of the receptor. The mutant EGFR may also transactivate other cell surface molecules, such as additional members of the EGFR family and the platelet-derived growth factor receptor, which ignite signaling cascades that synergize with the EGFR-initiated cascade. Because of the cell surface location and increased expression of the receptor along with its important biological function, EGFR has triggered much effort for designing targeted therapy. These approaches include TK inhibition, monoclonal antibody, vaccine, and RNA-based downregulation of the receptor. Treatment success requires that the drug penetrates the blood–brain barrier and has low systemic toxicity but high selectivity for the tumor. While the blockade of EGFR-dependent processes resulted in experimental and clinical treatment success, cells capable of using alternative signaling ultimately escape this strategy. A combination of interventions targeting tumor-specific cell surface regulators along with convergent downstream signaling pathways will likely enhance efficacy. Studies on EGFR in glioblastoma have revealed much information about the complexity of gliomagenesis and also facilitated the development of strategies for targeting drivers of tumor growth and combination therapies with increasing complexity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Adamczyk, K. A., Klein-Scory, S., Tehrani, M. M., Warnken, U., Schmiegel, W., Schnölzer, M., et al. (2011). Characterization of soluble and exosomal forms of the EGFR released from pancreatic cancer cells. Life Sciences, 89(9–10), 304–312.

    Article  PubMed  CAS  Google Scholar 

  • Agarwal, S., Sane, R., Oberoi, R., Ohlfest, J. R., & Elmquist, W. F. (2011). Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Reviews in Molecular Medicine, 13, e17.

    Article  PubMed  CAS  Google Scholar 

  • Altaba, A. R. (1999). Gli proteins encode context-dependent positive and negative functions: Implications for development and disease. Development, 126(14), 3205–3216.

    Google Scholar 

  • Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., et al. (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 26, 1626–1634.

    Article  PubMed  CAS  Google Scholar 

  • Andersson, U., Guo, D., Malmer, B., Bergenheim, A. T., Brännström, T., Hedman, H., et al. (2004). Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathology (Berlin), 108(2), 135–142.

    Article  CAS  Google Scholar 

  • Assi, H., Candolfi, M., Baker, G., Mineharu, Y., Lowenstein, P. R., & Castro, M. G. (2012). Gene therapy for brain tumors: Basic developments and clinical implementation. Neuroscience Letters, 527(2), 71–77.

    Article  PubMed  CAS  Google Scholar 

  • Babu, R., & Adamson, D. C. (2012). Rindopepimut an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma. Core Evidence, 7, 93–103.

    PubMed  CAS  Google Scholar 

  • Berezowska, S., & Schlegel, J. (2011). Targeting ErbB receptors in high-grade glioma. Current Pharmaceutical Design, 17(23), 2468–2487.

    Article  PubMed  CAS  Google Scholar 

  • Blesa, J. M., Mollá, S. B., Esparcia, M. F., Ortells, J. M., Godoy, M. P., Das, A. M., et al. (2012). Durable complete remission of a brainstem glioma treated with a combination of bevacizumab and cetuximab. Case Reports in Oncology, 5(3), 676–681.

    Article  PubMed  Google Scholar 

  • Boerner, J. L., Demory, M. L., Silva, C., & Parsons, S. J. (2004). Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II. Molecular and Cellular Biology, 24, 7059–7071.

    Article  PubMed  CAS  Google Scholar 

  • Bonavia, R., Inda, M. M., Vandenberg, S., Cheng, S. Y., Nagane, M., Hadwiger, P., et al. (2012). EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway. Oncogene, 31(36), 4054–4066.

    Article  PubMed  CAS  Google Scholar 

  • Bora, R. S., Gupta, D., Mukkur, T. K., & Saini, K. S. (2012). RNA interference therapeutics for cancer: Challenges and opportunities (review). Molecular Medicine Report, 6(1), 9–15.

    CAS  Google Scholar 

  • Brand, T. M., Iida, M., & Wheeler, D. L. (2011). Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biology & Therapy, 11(9), 777–792.

    Article  CAS  Google Scholar 

  • Bu, N., Wu, H., Sun, B., Zhang, G., Zhan, S., Zhang, R., et al. (2011). Exosome-loaded dendritic cells elicit tumor-specific CD8+ cytotoxic T cells in patients with glioma. Journal of Neuro-oncology, 104(3), 659–667.

    Article  PubMed  CAS  Google Scholar 

  • Cancer Genome Atlas Research Network. (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455(7216), 1061–1068.

    Article  CAS  Google Scholar 

  • Castro, A. S., Parente, B., Gonçalves, I., Antunes, A., Barroso, A., Conde, S., et al. (2013). Epidermal growth factor receptor mutation study for 5 years, in a population of patients with non-small cell lung cancer. Revista Portuguesa de Pneumologia, 19(1), 7–12.

    Article  PubMed  CAS  Google Scholar 

  • Clark, P. A., Iida, M., Treisman, D. M., Kalluri, H., Ezhilan, S., Zorniak, M., et al. (2012). Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition. Neoplasia, 14(5), 420–428.

    PubMed  CAS  Google Scholar 

  • Colman, H., Li, Z., Sulman, E. P., McDonald, J. M., Shooshtari, N. L., Rivera, A., et al. (2010). A multigene predictor of outcome in glioblastoma. Neuro-Oncology, 12(1), 49–57.

    Article  PubMed  CAS  Google Scholar 

  • Combs, S. E., Heeger, S., Haselmann, R., Edler, L., Debus, J., & Schulz-Ertner, D. (2006). Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)–phase I/II trial: Study protocol. BMC Cancer, 6, 133.

    Article  PubMed  CAS  Google Scholar 

  • Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., et al. (2004). Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New England Journal of Medicine, 351, 337–345.

    Article  PubMed  CAS  Google Scholar 

  • de Almeida Sassi, S. F., Lunardi Brunetto, A., Schwartsmann, G., Roesler, R., & Abujamra, A. L. (2012). Glioma revisited: From neurogenesis and cancer stem cells to the epigenetic regulation of the niche. Journal of Oncology, 2012, 537861.

    Article  PubMed  Google Scholar 

  • De Bacco, F., Casanova, E., Medico, E., Pellegatta, S., Orzan, F., Albano, R., et al. (2012). The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Research, 72(17), 4537–4550.

    Article  PubMed  CAS  Google Scholar 

  • Del Vecchio, C. A., Giacomini, C. P., Vogel, H., Jensen, K. C., Florio, T., Merlo, A., Pollack, J. R., Wong, A. J. (2012) EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms. Oncogene. doi:10.1038/onc.2012.280 [Epub ahead of print].

  • Del Vecchio, C. A., & Wong, A. J. (2010). Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Current Opinion in Molecular Therapeutics, 12(6), 741–754.

    PubMed  Google Scholar 

  • Dunn, G. P., Rinne, M. L., Wykosky, J., Genovese, G., Quayle, S. N., Dunn, I. F., et al. (2012). Emerging insights into the molecular and cellular basis of glioblastoma. Genes & Development, 26(8), 756–784.

    Article  CAS  Google Scholar 

  • Eller, J. L., Longo, S. L., Kyle, M. M., Bassano, D., Hicklin, D. J., & Canute, G. W. (2005). Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery, 56(1), 155–162.

    PubMed  Google Scholar 

  • Emrich, J. G., Brady, L. W., Quang, T. S., Class, R., Miyamoto, C., Black, P., et al. (2002). Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: Ten-year synopsis of a novel treatment. American Journal of Clinical Oncology, 25(6), 541–546.

    Article  PubMed  Google Scholar 

  • Fan, Q. W., & Weiss, W. A. (2010). Targeting the RTK-PI3K-mTOR axis in malignant glioma: Overcoming resistance. Current Topics in Microbiology and Immunology, 347, 279–296.

    Article  PubMed  CAS  Google Scholar 

  • Feng, H., Hu, B., Jarzynka, M. J., Li, Y., Keezer, S., Johns, T. G., et al. (2012). Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 109(8), 3018–3023.

    Article  PubMed  CAS  Google Scholar 

  • Fenton, T. R., Nathanson, D., Ponte de Albuquerque, C., Kuga, D., Iwanami, A., Dang, J., et al. (2012). Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proceedings of the National Academy of Sciences of the United States of America, 109(35), 14164–14169.

    Article  PubMed  CAS  Google Scholar 

  • Forbes, S. A., Tang, G., Bindal, N., Bamford, S., Dawson, E., Cole, C., et al. (2010). COSMIC (the Catalogue of Somatic Mutations in Cancer): A resource to investigate acquired mutations in human cancer. Nucleic Acids Research, 38(Database issue):D652-D657. PMCID:PMC2808858.

    Google Scholar 

  • Gan, H. K., Lappas, M., Cao, D. X., Cvrljevdic, A., Scott, A. M., & Johns, T. G. (2009). Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalization. Journal of Cellular and Molecular Medicine, 13(9), 3993–4001.

    Article  PubMed  Google Scholar 

  • Graner, M. W., Alzate, O., Dechkovskaia, A. M., Keene, J. D., Sampson, J. H., Mitchell, D. A., et al. (2009). Proteomic and immunologic analyses of brain tumor exosomes. FASEB Journal, 23(5), 1541–1557.

    Article  PubMed  CAS  Google Scholar 

  • Guo, D., Wang, B., Han, F., & Lei, T. (2010). RNA interference therapy for glioblastoma. Expert Opinion on Biological Therapy, 10(6), 927–936.

    Article  PubMed  CAS  Google Scholar 

  • Guryanova, O. A., Wu, Q., Cheng, L., Lathia, J. D., Huang, Z., Yang, J., et al. (2011). Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell, 19(4), 498–511.

    Article  PubMed  CAS  Google Scholar 

  • Halatsch, M. E., Gehrke, E. E., Vougioukas, V. I., Bötefür, I. C., A-Borhani, F., Efferth, T., et al. (2004). Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines. Journal of Neurosurgery, 100(3), 523–533.

    Article  PubMed  CAS  Google Scholar 

  • Halatsch, M. E., Löw, S., Mursch, K., Hielscher, T., Schmidt, U., Unterberg, A., et al. (2009). Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. Laboratory investigation. Journal of Neurosurgery, 111(2), 211–218.

    Article  PubMed  CAS  Google Scholar 

  • Halatsch, M. E., Schmidt, U., Bötefür, I. C., Holland, J. F., & Ohnuma, T. (2000). Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA. Journal of Neurosurgery, 92(2), 297–305.

    Article  PubMed  CAS  Google Scholar 

  • Hasselbalch, B., Lassen, U., Hansen, S., Holmberg, M., Sørensen, M., Kosteljanetz, M., et al. (2010). Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: A phase II trial. Neuro-Oncology, 12(5), 508–516.

    PubMed  CAS  Google Scholar 

  • Hau, P., Jachimczak, P., Schlaier, J., & Bogdahn, U. (2011). TGF-β2 signaling in high-grade gliomas. Current Pharmaceutical Biotechnology, 12(12), 2150–2157.

    Article  PubMed  CAS  Google Scholar 

  • Hegi, M. E., Diserens, A. C., Gorlia, T., Hamou, M. F., de Tribolet, N., Weller, M., et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. New England Journal of Medicine, 352(10), 997–1003.

    Article  PubMed  CAS  Google Scholar 

  • Hegi, M. E., Rajakannu, P., & Weller, M. (2012). Epidermal growth factor receptor: A re-emerging target in glioblastoma. Current Opinion in Neurology, 25(6), 774–779.

    Article  PubMed  CAS  Google Scholar 

  • Huang, P. H., Mukasa, A., Bonavia, R., Flynn, R. A., Brewer, Z. E., Cavenee, W. K., et al. (2007). Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proceedings of the National Academy of Sciences, 104, 12867–12872.

    Article  CAS  Google Scholar 

  • Hynes, N. E., & Lane, H. A. (2005). ERBB receptors and cancer: The complexity of targeted inhibitors. Nature Reviews Cancer, 5, 341–354.

    Article  PubMed  CAS  Google Scholar 

  • Idbaih, A., Aimard, J., Boisselier, B., Marie, Y., Paris, S., Criniere, E., et al. (2009). Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma. Neuropathology and Applied Neurobiology, 35(2), 208–213.

    Article  PubMed  CAS  Google Scholar 

  • Inda, M. M., Bonavia, R., Mukasa, A., Narita, Y., Sah, D. W., Vandenberg, S., et al. (2010). Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes & Development, 24, 1731–1745.

    Article  CAS  Google Scholar 

  • Jarboe, J. S., Dutta, S., Velu, S. E., Willey, C. D. (2012). Mini-review: Bmx Kinase Inhibitors for Cancer Therapy. Recent Patents on Anti-Cancer Drug Discovery, 29 [Epub ahead of print].

  • Ji, H., Sharpless, N. E., & Wong, K. K. (2006). EGFR targeted therapy: View from biological standpoint. Cell Cycle, 5(18), 2072–2076.

    Article  PubMed  CAS  Google Scholar 

  • Jin, X., Jin, X., Sohn, Y. W., Yin, J., Kim, S. H., Joshi, K., et al. (2013). Blockade of EGFR signaling promotes glioma stem-like cell invasiveness by abolishing ID3-mediated inhibition of p27(KIP1) and MMP3 expression. Cancer Letters, 328(2), 235–242.

    Article  PubMed  CAS  Google Scholar 

  • Johns, T. G., Perera, R. M., Vernes, S. C., Vitali, A. A., Cao, D. X., Cavenee, W. K., et al. (2007). The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clinical Cancer Research, 13, 1911–1925.

    Article  PubMed  CAS  Google Scholar 

  • Johnson, H., Del Rosario, A. M., Bryson, B. D., Schroeder, M. A., Sarkaria, J. N., & White, F. M. (2012). Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts. Molecular and Cellular Proteomics, 11(12), 1724–1740.

    Article  PubMed  CAS  Google Scholar 

  • Kang, C. S., Zhang, Z. Y., Jia, Z. F., Wang, G. X., Qiu, M. Z., Zhou, H. X., et al. (2006). Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo. Cancer Gene Therapy, 13(5), 530–538.

    Article  PubMed  CAS  Google Scholar 

  • Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O’Callaghan, C. J., Tu, D., Tebbutt, N. C., et al. (2008). K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New England Journal of Medicine, 359, 1757–1765.

    Article  PubMed  CAS  Google Scholar 

  • Karpel-Massler, G., Schmidt, U., Unterberg, A., & Halatsch, M. E. (2009). Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: Where do we stand? Molecular Cancer Research, 7(7), 1000–1012.

    Article  PubMed  CAS  Google Scholar 

  • Kim, C., Shah, B. P., Subramaniam, P., & Lee, K. B. (2011). Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs. Molecular Pharmaceutics, 8(5), 1955–1961.

    Article  PubMed  CAS  Google Scholar 

  • Kohno, M., Horibe, T., Haramoto, M., Yano, Y., Ohara, K., Nakajima, O., et al. (2011). A novel hybrid peptide targeting EGFR-expressing cancers. European Journal of Cancer, 47(5), 773–783.

    Article  PubMed  CAS  Google Scholar 

  • Le Mercier, M., Hastir, D., Lopez, X. M., De Néve, N., Maris, C., Trepant, A. L., et al. (2012). A simplified approach for the molecular classification of glioblastomas. PLoS ONE, 7(9), e45475.

    Article  PubMed  CAS  Google Scholar 

  • Lee, J. C., Vivanco, I., Beroukhim, R., Huang, J. H., Feng, W. L., DeBiasi, R. M. et al., (2006) Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 3(12),e485.

  • Li, M., Mukasa, A., Inda, M. M., Zhang, J., Chin, L., Cavenee, W., et al. (2011). Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. The Journal of Experimental Medicine, 208(13), 2657–2673.

    Article  PubMed  CAS  Google Scholar 

  • Li, L., Quang, T. S., Gracely, E. J., Kim, J. H., Emrich, J. G., Yaeger, T. E., et al. (2010). A phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. Journal of Neurosurgery, 113(2), 192–198.

    Article  PubMed  Google Scholar 

  • Liu, T. F., Hall, P. D., Cohen, K. A., Willingham, M. C., Cai, J., Thorburn, A., et al. (2005). Interstitial diphtheria toxin epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clinical Cancer Research, 11(1), 329–334.

    PubMed  CAS  Google Scholar 

  • Liu, Y., Li, C., & Lin, J. (2010). STAT3 as a therapeutic target for glioblastoma. Anti-Cancer Agents in Medicinal Chemistry, 10(7), 512–519.

    Article  PubMed  CAS  Google Scholar 

  • Loew, S., Schmidt, U., Unterberg, A., & Halatsch, M. E. (2009). The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. Anti-Cancer Agents in Medicinal Chemistry, 9(6), 703–715.

    Article  PubMed  CAS  Google Scholar 

  • Longo, S. L., Padalino, D. J., McGillis, S., Petersen, K., Schirok, H., Politz, O., et al. (2012). Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models. Investigational New Drugs, 30(6), 2161–2172.

    Article  PubMed  CAS  Google Scholar 

  • Luwor, R. B., Johns, T. G., Murone, C., Huang, H. J., Cavenee, W. K., Ritter, G., et al. (2001). Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Research, 61(14), 5355–5361.

    PubMed  CAS  Google Scholar 

  • Marsh, J. C., Goldfarb, J., Shafman, T. D., & Aidnag, Z. D. (2012). Current status of immunotherapy and gene therapy for high-grade gliomas. Cancer Control, 20(1), 43–48.

    Google Scholar 

  • Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S. J., Dia, E. Q., et al. (2005). Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. New England Journal of Medicine, 353, 2012–2024.

    Article  PubMed  CAS  Google Scholar 

  • Meng, W., Jiang, L., Lu, L., Hu, H., Yu, H., Ding, D., et al. (2012). Anti-miR-155 oligonucleotide enhances chemosensitivity of U251 cell to taxol by inducing apoptosis. Cell Biology International, 36(7), 653–659.

    Article  PubMed  CAS  Google Scholar 

  • Mengelberger, D., Kern, D., Loipetzberger, A., Eberl, M., & Aberger, F. (2012). Cooperative hedgehog-EGFR signaling. Frontiers in Bioscience, 17, 90–99.

    Article  Google Scholar 

  • Mineo, J. F., Bordron, A., Baroncini, M., Maurage, C. A., Ramirez, C., Siminski, R. M., et al. (2007). Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. Journal of Neuro-oncology, 85(3), 281–287.

    Article  PubMed  Google Scholar 

  • Moyer, J. D., Barbacci, E. G., Iwata, K. K., Arnold, L., Boman, B., Cunningham, A., et al. (1997). Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Research, 57(21), 4838–4848.

    PubMed  CAS  Google Scholar 

  • Noerholm, M., Balaj, L., Limperg, T., Salehi, A., Zhu, L. D., Hochberg, F. H., et al. (2012). RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. BMC Cancer, 17(12), 22.

    Article  CAS  Google Scholar 

  • Ou, S. H. (2012). Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence. Critical Reviews in Oncology Hematology, 83(3), 407–421.

    Article  Google Scholar 

  • Peereboom, D. M., Shepard, D. R., Ahluwalia, M. S., Brewer, C. J., Agarwal, N., Stevens, G. H., et al. (2010). Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. Journal of Neuro-oncology, 98(1), 93–99.

    Article  PubMed  CAS  Google Scholar 

  • Prayson, R. A. (2009). Lipomatous supratentorial primitive neuroectodermal tumor with glioblastomatous differentiation. Annals of Diagnostic Pathology, 13, 36–40.

    Article  PubMed  Google Scholar 

  • Quang, T. S., & Brady, L. W. (2004). Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. International Journal of Radiation Oncology Biology Physics, 58(3), 972–975.

    Article  CAS  Google Scholar 

  • Quatrale, A. E., Porcelli, L., Silvestris, N., Colucci, G., Angelo, A., & Azzariti, A. (2011). EGFR tyrosine kinases inhibitors in cancer treatment: In vitro and in vivo evidence. Frontiers in Bioscience, 16, 1962–1972.

    Article  PubMed  CAS  Google Scholar 

  • Raizer, J. J., Abrey, L. E., Lassman, A. B., Chang, S. M., Lamborn, K. R., Kuhn, J. G., et al. (2010). A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-Oncology, 12(1), 95–103.

    Article  PubMed  CAS  Google Scholar 

  • Rich, J. N., Rasheed, B. K., & Yan, H. (2004). EGFR mutations and sensitivity to gefitinib. New England Journal of Medicine, 351(12), 1260–1261.

    Article  PubMed  CAS  Google Scholar 

  • Rivera, F., Vega-Villegas, M. E., & Lopez-Brea, M. F. (2008). Cetuximab, its clinical use and future perspectives. Anti-Cancer Drugs, 19(2), 99–113.

    Article  PubMed  CAS  Google Scholar 

  • Sai, K., Wang, S., Balasubramaniyan, V., Conrad, C., Lang, F. F., Aldape, K., et al. (2012). Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway. Journal of Neuro-oncology, 107(3), 487–501.

    Article  PubMed  CAS  Google Scholar 

  • Sampson, J. H., Archer, G. E., Mitchell, D. A., Heimberger, A. B., Herndon, J. E., 2nd, Lally-Goss, D., et al. (2009). An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Molecular Cancer Therapeutics, 8(10), 2773–2779.

    Article  PubMed  CAS  Google Scholar 

  • Schneider, T., Becker, A., Ringe, K., Reinhold, A., Firsching, R., & Sabel, B. A. (2008). Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles. Journal of Neuroimmunology, 195(1–2), 21–27.

    Article  PubMed  CAS  Google Scholar 

  • Scott, A. M., Lee, F. T., Tebbutt, N., Herbertson, R., Gill, S. S., Liu, Z., et al. (2007). A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proceedings of the National Academy of Sciences of the United States of America, 104(10), 4071–4076.

    Article  PubMed  CAS  Google Scholar 

  • Shao, H., Chung, J., Balaj, L., Charest, A., Bigner, D. D., Carter, B. S., et al. (2012). Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nature Medicine, 18(12), 1835–1840.

    Article  PubMed  CAS  Google Scholar 

  • Shin, B. J., Burkhardt, J. K., Riina, H. A., & Boockvar, J. A. (2012). Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: A technical case series. Neurosurgery Clinics of North America, 23(2), 323–329.

    Article  PubMed  Google Scholar 

  • Shinojima, N., Tada, K., Shiraishi, S., Kamiryo, T., Kochi, M., Nakamura, H., et al. (2003). Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Research, 63, 6962–6970.

    PubMed  CAS  Google Scholar 

  • Shir, A., & Levitzki, A. (2002). Inhibition of glioma growth by tumor-specific activation of double-stranded RNA-dependent protein kinase PKR. Nature Biotechnology, 20(9), 895–900.

    Article  PubMed  CAS  Google Scholar 

  • Singh, A. B., & Harris, R. C. (2005). Autocrine, paracrine and juxtacrine signaling by EGFR ligands. Cellular Signalling, 17, 1183–1193.

    Article  PubMed  CAS  Google Scholar 

  • Skog, J., Würdinger, T., van Rijn, S., Meijer, D. H., Gainche, L., Sena-Esteves, M., et al. (2008). Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nature Cell Biology, 10(12), 1470–1476.

    Article  PubMed  CAS  Google Scholar 

  • Stechishin, O. D., Luchman, H. A., Ruan, Y., Blough, M. D., Nguyen, S. A., Kelly, J. J., et al. (2013). On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells. Neuro-Oncology, 15(2), 198–207.

    Article  PubMed  CAS  Google Scholar 

  • Stockhausen, M. T., Broholm, H., Villingshoj, M., Kirchhoff, M., Gerdes, T., Kristoffersen, K., et al. (2011). Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme. Experimental Cell Research, 317, 1513–1526.

    Article  PubMed  CAS  Google Scholar 

  • Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., et al. (2007). Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science, 318, 287–290.

    Article  PubMed  CAS  Google Scholar 

  • Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The lancet Oncology, 10(5), 459–466.

    Article  PubMed  CAS  Google Scholar 

  • Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine, 352(10), 987–996.

    Article  PubMed  CAS  Google Scholar 

  • Tanaka, K., Babic, I., Nathanson, D., Akhavan, D., Guo, D., Gini, B., et al. (2011). Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discovery, 1(6), 524–538.

    Article  PubMed  CAS  Google Scholar 

  • Tanaka, S., Louis, D. N., Curry, W. T., Batchelor, T. T., & Dietrich, J. (2012). Diagnostic and therapeutic avenues for glioblastoma: No longer a dead end? Natural Review of Clinical Oncology, 10(1), 14–26.

    Article  CAS  Google Scholar 

  • Taylor, T. E., Furnari, F. B., & Cavenee, W. K. (2012). Targeting EGFR for treatment of glioblastoma: Molecular basis to overcome resistance. Current Cancer Drug Targets, 12(3), 197–209.

    Article  PubMed  CAS  Google Scholar 

  • Taylor, D. D., & Gercel-Taylor, C. (2011). Exosomes/microvesicles: Mediators of cancer-associated immunosuppressive microenvironments. Seminars in Immunopathology, 33(5), 441–454.

    Article  PubMed  CAS  Google Scholar 

  • The Cancer Genome Atlas (TCGA) Research Network. (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455, 1061–1068.

    Article  CAS  Google Scholar 

  • Thiessen, B., Stewart, C., Tsao, M., Kamel-Reid, S., Schaiquevich, P., Mason, W., et al. (2010). A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: Clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemotherapy and Pharmacology, 65(2), 353–361.

    Article  PubMed  CAS  Google Scholar 

  • Thomas, C. Y., Chouinard, M., Cox, M., Parsons, S., Stallings-Mann, M., Garcia, R., et al. (2003). Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells. International Journal of Cancer, 104(1), 19–27.

    Article  CAS  Google Scholar 

  • Torp, S. H., Gulati, S., Johannessen, E., & Dalen, A. (2007). Coexpression of c-erbB 1–4 receptor proteins in human glioblastomas. An immunohistochemical study. Journal of Experimental & Clinical Cancer Research, 26(3), 353–359.

    CAS  Google Scholar 

  • Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., et al. (1984). Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature, 309, 418–425.

    Article  PubMed  CAS  Google Scholar 

  • van den Bent, M. J., Brandes, A. A., Rampling, R., Kouwenhoven, M. C., Kros, J. M., Carpentier, A. F., et al. (2009a). Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. Journal of Clinical Oncology, 27(8), 1268–1274.

    Article  PubMed  CAS  Google Scholar 

  • van den Bent, M. J., Vogelbaum, M. A., Wen, P. Y., Macdonald, D. R., & Chang, S. M. (2009b). End point assessment in gliomas: Novel treatments limit usefulness of classical Macdonald’s Criteria. Journal of Clinical Oncology, 27(18), 2905–2908.

    Article  PubMed  Google Scholar 

  • Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., & The Cancer Genome Atlas Research Network. (2010). An integrated analysis identifies clinically relevant subtypes of glioblastome characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell, 17(1), 98.

    Article  PubMed  CAS  Google Scholar 

  • Vivanco, I., Robins, H. I., Rohle, D., Campos, C., Grommes, C., Nghiemphu, P. L., et al. (2012). Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discovery, 2(5), 458–471.

    Article  PubMed  CAS  Google Scholar 

  • Wang, S. C., & Hung, M. C. (2009). Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clinical Cancer Research, 15(21), 6484–6489.

    Article  PubMed  CAS  Google Scholar 

  • Watanabe, K., Tachibana, O., Sata, K., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (1996). Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathology, 6(3), 217–223.

    Article  PubMed  CAS  Google Scholar 

  • Wells, A. (1999). EGF receptor. International Journal of Biochemistry & Cell Biology, 31(6), 637–643.

    Article  CAS  Google Scholar 

  • Wissner, A., & Mansour, T. S. (2008). The development of HKI-272 and related compounds for the treatment of cancer. Archiv der Pharmazie (Weinheim), 341(8), 465–477.

    Article  CAS  Google Scholar 

  • Wong, S. T., Zhang, X. Q., Zhuang, J. T., Chan, H. L., Li, C. H., & Leung, G. K. (2012). MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells. Anticancer Research, 32(7), 2835–2841.

    PubMed  CAS  Google Scholar 

  • Yamazaki, H., Kijima, H., Ohnishi, Y., Abe, Y., Oshika, Y., Tsuchida, T., et al. (1998). Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor. JNCI Journal of the National Cancer Institute, 90(8), 581.

    Article  CAS  Google Scholar 

  • Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., et al. (2009). IDH1 and IDH2 mutations in gliomas. New England Journal of Medicine, 360(8), 765–773.

    Article  PubMed  CAS  Google Scholar 

  • Yang, X. D., Jia, X. C., Corvalan, J. R. F., Wang, P., & Davis, C. G. (2001). Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Critical Reviews in Oncology and Hematology, 38, 17–23.

    Article  CAS  Google Scholar 

  • Yang, Y., Jiang, H., Gao, H., Kong, J., Zhang, P., Hu, S., et al. (2012). The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. Neoplasia, 14(6), 509–518.

    PubMed  Google Scholar 

  • Yoon, H., Kim, D. J., Ahn, E. H., Gellert, G. C., Shay, J. W., Ahn, C. H., et al. (2009). Antitumor activity of a novel antisense oligonucleotide against Akt1. Journal of Cellular Biochemistry, 108(4), 832–838.

    Article  PubMed  CAS  Google Scholar 

  • Yung, W. K., Vredenburgh, J. J., Cloughesy, T. F., Nghiemphu, P., Klencke, B., Gilbert, M. R., et al. (2010). Safety and efficacy of erlotinib in first-relapse glioblastoma: A phase II open-label study. Neuro-Oncology, 12(10), 1061–1070.

    Article  PubMed  CAS  Google Scholar 

  • Zaczek, A., Brandt, B., & Bielawski, K. P. (2005). The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histology and Histopathology, 20(3), 1005–1015.

    PubMed  CAS  Google Scholar 

  • Zeineldin, R., Ning, Y., & Hudson, L. G. (2010). The constitutive activity of epidermal growth factor receptor vIII leads to activation and differential trafficking of wild-type epidermal growth factor receptor and erbB2. Journal of Histochemistry and Cytochemistry, 58(6), 529–541.

    Article  PubMed  CAS  Google Scholar 

  • Zhou, X., Ren, Y., Moore, L., Mei, M., You, Y., Xu, P., et al. (2010). Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Laboratory Investigation, 90(2), 144–155.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank to Katalin Kovago for the electronic preparation of figures. Grant support to DEP was provided by the Carol M. Baldwin Breast Cancer Research Fund, the Upstate Golisano Children’s Hospital/Children’s Miracle Network, and the George W. Perkins III endowment for Neurosurgery at SUNY Upstate Medical University.

Author information

Authors and Affiliations

  1. Departments of Molecular Medicine, Markusovszky Hospital, Markusovszky Street 5, 9700, Szombathely, Hungary

    B. Kalman

  2. Department of Pathology, Markusovszky Hospital, Szombathely, Hungary

    E. Szep & F. Garzuly

  3. Department of Neurosurgery, SUNY Upstate Medical University, Syracuse, NY, USA

    D. E. Post

Authors
  1. B. Kalman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Szep
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Garzuly
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. E. Post
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Kalman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kalman, B., Szep, E., Garzuly, F. et al. Epidermal Growth Factor Receptor as a Therapeutic Target in Glioblastoma. Neuromol Med 15, 420–434 (2013). https://doi.org/10.1007/s12017-013-8229-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12017-013-8229-y

Keywords

Search

Navigation